Pancreatic cancer in 2021: What you need to know to win

Published on Sep 21, 2021in World Journal of Gastroenterology5.742
· DOI :10.3748/WJG.V27.I35.5851
Valeria Tonini9
Estimated H-index: 9
(UNIBO: University of Bologna),
Manuel Zanni
#1Kung-Kai Kuo (KMU: Kaohsiung Medical University)H-Index: 22
#2Pi-Jung Hsiao (ISU: I-Shou University)H-Index: 2
Last. Kohsuke Kato (University of Tsukuba)H-Index: 10
view all 13 authors...
The high mortality of pancreatic cancer is attributed to the insidious progression of this disease, which results in a delayed diagnosis and advanced disease stage at diagnosis. More than 35% of patients with pancreatic cancer are in stage III, whereas 50% are in stage IV at diagnosis. Thus, understanding the aggressive features of pancreatic cancer will contribute to the resolution of problems, such as its early recurrence, metastasis, and resistance to chemotherapy and radiotherapy. Therefore,...
#1Gabriella CirmenaH-Index: 17
#2Martina DameriH-Index: 2
Last. Gabriele ZoppoliH-Index: 23
view all 6 authors...
Current approaches for cancer detection and characterization are based on radiological procedures coupled with tissue biopsies, despite relevant limitations in terms of overall accuracy and feasibility, including relevant patients’ discomfort. Liquid biopsies enable the minimally invasive collection and analysis of circulating biomarkers released from cancer cells and stroma, representing therefore a promising candidate for the substitution or integration in the current standard of care. Despite...
#1Greta Brezgyte (QMUL: Queen Mary University of London)H-Index: 1
#2Vinay Shah (QMUL: Queen Mary University of London)H-Index: 1
Last. Tatjana Crnogorac-Jurcevic (QMUL: Queen Mary University of London)H-Index: 36
view all 4 authors...
Pancreatic ductal adenocarcinoma (PDAC) carries a deadly diagnosis, due in large part to delayed presentation when the disease is already at an advanced stage. CA19-9 is currently the most commonly utilized biomarker for PDAC; however, it lacks the necessary accuracy to detect precursor lesions or stage I PDAC. Novel biomarkers that could detect this malignancy with improved sensitivity (SN) and specificity (SP) would likely result in more curative resections and more effective therapeutic inter...
#1Ibrahim Nassour (University of Pittsburgh)H-Index: 16
#2Samer Tohme (University of Pittsburgh)H-Index: 21
Last. Paniccia Alessandro (University of Pittsburgh)H-Index: 1
view all 6 authors...
BACKGROUND: Emerging data from multi-institutional and national databases suggest that robotic pancreaticoduodenectomy is safe and feasible for pancreatic adenocarcinoma. Nevertheless, there are limited reports evaluating its safety and oncologic efficacy following neoadjuvant chemotherapy. METHOD: This is a retrospective study from the 2010-2016 National Cancer Database comparing the postoperative, pathological and long-term oncologic outcomes between robotic pancreaticoduodenectomy (RPD) and o...
#1Claudio Ricci (UNIBO: University of Bologna)H-Index: 30
#2Carlo Ingaldi (UNIBO: University of Bologna)H-Index: 7
Last. Riccardo Casadei (UNIBO: University of Bologna)H-Index: 33
view all 8 authors...
BACKGROUND The superiority of Blumgart anastomosis (BA) over non-BA duct to mucosa (non-BA DtoM) still remains under debate. METHODS We performed a systematic search of studies comparing BA to non-BA DtoM. The primary endpoint was CR-POPF. Postoperative morbidity and mortality, post-pancreatectomy hemorrhage (PPH), delayed gastric emptying (DGE), reoperation rate, and length of stay (LOS) were evaluated as secondary endpoints. The meta-analysis was carried out using random effect. The results we...
#1Kennichi Satoh (Tohoku Pharmaceutical University)H-Index: 45
Pancreatic ductal adenocarcinoma (PDAC) is the most malignant form of gastrointestinal tumor and is the fourth leading cause of deaths due to cancer in Japan. This cancer shows a poor outcome due to the difficulty of its early diagnosis and its rapid growth. Once this disease becomes clinically evident, it is frequently accompanied by distant metastasis at the time of diagnosis. A recent multicenter study in Japan revealed that patients with the early stage of this disease (stage 0 and I) showed...
#1Jia Wu (ZJU: Zhejiang University)H-Index: 2
#2Jian-Ting Cai (ZJU: Zhejiang University)H-Index: 4
Pancreatic cancer is a tumor with a high degree of malignancy, morbidity, and mortality. Immunotherapy is another important treatment for pancreatic cancer in addition to surgery and chemotherapy, but its application in pancreatic cancer is very limited, which is related to the unique biological behavior of pancreatic cancer and the tumor microenvironment. The immunosuppressive microenvironment of pancreatic cancer is highly heterogeneous and presents challenges for immunotherapy. The transforma...
Objective Recently, tumours with microsatellite instability (MSI)/defective DNA mismatch repair (dMMR) have gained considerable interest due to the success of immunotherapy in this molecular setting. Here, we aim to clarify clinical-pathological and/or molecular features of this tumour subgroup through a systematic review coupled with a comparative analysis with existing databases, also providing indications for a correct approach to the clinical identification of MSI/dMMR pancreatic ductal aden...
#1Junqi Liu (Guangxi Medical University)H-Index: 4
#2Xiwen Liao (Guangxi Medical University)H-Index: 15
Last. Tao Peng (Guangxi Medical University)H-Index: 22
view all 16 authors...
This study explored the prognostic significance of Glypican (GPC) family genes in patients with pancreatic ductal adenocarcinoma (PDAC) after pancreaticoduodenectomy using data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). A total of 112 PDAC patients from TCGA and 48 patients from GEO were included in the analysis. The relationship between overall survival and the expression of GPC family genes as well as basic clinical characteristics was analyzed using the Kaplan-Meie...
#1Peng JiangH-Index: 1
#2Ming ZhangH-Index: 1
Last. Kai ZhangH-Index: 1
view all 4 authors...
ObjectivePancreatic adenocarcinoma (PAAD) is one of the most lethal malignant tumors worldwide. Various studies based on cell lines, preclinical mouse models, and human tissue samples have shown th...
Cited By0
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.